Cutler Group LP Akebia Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$0.32 - $0.67 $3,680 - $7,705	-11,500 Reduced 29.04%	28,100 $0
Q1 2022 Apr 14, 2022	BUY	$0.72 - $2.93 $28,152 - $114,563	39,100 Added 7820.0%	39,600 $0
Q4 2020 Jan 21, 2021	SELL	$2.22 - $3.78 $2,220 - $3,780	-1,000 Reduced 66.67%	500 $0
Q3 2020 Oct 27, 2020	BUY	$2.39 - $13.08 $3,585 - $19,620	1,500 New	1,500 $0
Q2 2018 Aug 10, 2018	SELL	$9.15 - $11.34 $22,875 - $28,350	-2,500 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$9.53 - $15.68 $25,731 - $42,336	-2,700 Reduced 51.92%	2,500 $0
Q4 2017 Jan 17, 2018	SELL	$14.24 - $19.59 $45,568 - $62,688	-3,200 Reduced 38.1%	5,200 $1,000
Q3 2017 Oct 17, 2017	BUY	$13.06 - $19.67 $109,704 - $165,228	8,400	8,400 $26,000

121

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $395M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.